VERAXA Biotech AG (NASDAQ: VRXA) has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase into the next stage of development, following the successful completion of its collaboration with OmniAb Inc. The partnership, which began in May 2025 (https://nnw.fm/nIprz), delivered a portfolio of therapeutic antibody binders, and VERAXA is now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation. This milestone underscores the company's progress in building a diversified oncology pipeline.
Although VXA-222 is not based on VERAXA's proprietary BiTAC platform, it leverages the company's antibody engineering, linker, and conjugation technologies, making it one of its more advanced development programs. The advancement of VXA-222 is a key step in VERAXA's strategy to develop novel therapies for difficult-to-treat cancers, with the program now moving toward preclinical studies and eventual clinical trials.
In parallel, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP estate is critical for safeguarding the company's innovative platforms and ensuring long-term competitive advantage.
The expansion of the patent portfolio reflects VERAXA's commitment to building a comprehensive and defensible position in the rapidly evolving field of antibody-based cancer therapies. By protecting its proprietary technologies, the company aims to create significant value for shareholders and partners while advancing its pipeline.
VERAXA continues to build a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats. The company's focus on next-generation antibody technologies positions it to address significant unmet medical needs in oncology. With the VXA-222 program moving forward and the IP portfolio growing, VERAXA is well-positioned to capitalize on its innovative research and development efforts.
The news of VXA-222's advancement and the expansion of the patent portfolio comes as part of VERAXA's broader efforts to establish itself as an emerging leader in cancer therapy development. The company's progress highlights its ability to execute on its strategic objectives and underscores the potential of its proprietary technologies to deliver meaningful improvements in patient outcomes.
